Report: Moderna Sets Price Range for Coronavirus Vaccine

Considered by many observers to be the leader in the hunt for a coronavirus vaccine, Moderna (NASDAQ: MRNA) has apparently settled on a price for its potential blockbuster product. Citing "people familiar with talks between the company and potential buyers," the Financial Times reported Tuesday that the company aims to sell its vaccine at roughly $50 to $60 per two-dose treatment course.

That price applies to relatively prosperous countries such as the U.S. The article quoted "other people familiar with the plans" saying that the young biotech company has prioritized these markets. The report's sources claim that Moderna's pricing "causes considerable concern and difficulties in negotiations, in view of the fact that other companies have pledged much lower prices."

Image source: Getty Images.

Continue reading

Source Fool.com